<DOC>
	<DOC>NCT00213694</DOC>
	<brief_summary>Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.</brief_summary>
	<brief_title>PROSTACOX : Metastatic Prostate Chemotherapy</brief_title>
	<detailed_description>Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>metastatic prostate cancer ASCO progression criteria other prostate chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>